GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 20 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

PRTK Dividend Payout History


# Declaration Date Ex-Date Pay Date Amount Yield
1 Oct 14, 2014 Oct 31, 2014 Oct 29, 2014 $8.01 39.96%
2 Oct 22, 2014 Oct 22, 2014 Oct 22, 2014 $8.00 36.19%
3 May 14, 2014 Jun 04, 2014 Jun 03, 2014 $15.96 71.25%
4 May 21, 2014 May 21, 2014 Jun 03, 2014 $15.96 71.25%

FAQ

What is the symbol for Paratek Pharmaceuticals Stock and on which exchange is it traded?
The symbol for Paratek Pharmaceuticals is PRTK and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Paratek Pharmaceuticals Stock?
Paratek Pharmaceuticals holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Paratek Pharmaceuticals Stock?
Paratek Pharmaceuticals Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Paratek Pharmaceuticals Stock.

What's the current price of Paratek Pharmaceuticals Stock?
As of the end of day on the 2023-12-19, the price of an Paratek Pharmaceuticals (PRTK) share was $2.23.

What is the 52-week high and low for Paratek Pharmaceuticals Stock?
The 52-week high for Paratek Pharmaceuticals Stock is $2.91 and the 52-week low is $1.29.

What is the market capitalization of Paratek Pharmaceuticals Stock?
As of the 2023-12-19, the market capitalization of Paratek Pharmaceuticals is 127.829M.
Click to get the best stock tips daily for free!

About Paratek Pharmaceuticals

Paratek Pharmaceuticals Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute ... PRTK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT